Millendo Therapeutics Inc (NASDAQ:MLND) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price target of $26.50 for the company and are anticipating that the company will post ($0.78) earnings per share for the current quarter, according to Zacks. Zacks has also given Millendo Therapeutics an industry rank of 64 out of 256 based on the ratings given to related companies.

MLND has been the subject of several recent analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Millendo Therapeutics in a research report on Friday, January 4th. They set a “buy” rating and a $29.00 price objective for the company. ValuEngine raised shares of Millendo Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 2nd. Finally, Leerink Swann initiated coverage on shares of Millendo Therapeutics in a research report on Thursday, December 13th. They set an “outperform” rating and a $24.00 price objective for the company.

Shares of MLND stock traded up $0.82 on Friday, hitting $11.19. The company’s stock had a trading volume of 4,600 shares, compared to its average volume of 12,677. Millendo Therapeutics has a fifty-two week low of $6.77 and a fifty-two week high of $17.40. The company has a market capitalization of $121.78 million, a PE ratio of -0.53 and a beta of 3.06.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

See Also: What is Depreciation?

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with's FREE daily email newsletter.